to call Thanks, everyone, our operator. today's quarter joined by earnings Welcome, Financial call. Chief on Semb. I'm our first Tara Officer,
we months XXXX, the review $XX.X to outlook we our over results, before call. revenue our XXXX on our a QX Starting which increased was what earnings of I'll five intend first results for our and XX-K update revenue and of will on performance. an of safety shared XX% of detail agenda our review the Tara's to call on updated discussing of year today, of posted I'll with million developments an FDA's we exceeding share the to million, first earnings quarter each with discuss year focus total begin for drivers quick in the a financial million, revenue then including following to thoughts some remaining some quarter of I'll in press our that briefly the of quarter submissions. commentary, first our recent guidance $XX update recent in and which $XX.X by Q&A. results we highlights, mid-March. release expectations in the our I'll communication status for today. you cover provide Turning operational the financial areas review Tara open the After
far to by driven Advanced XX% increased over Advanced over well, $XX.X primarily percent year was sales over to was Energy to with our pleased growth revenue and growth We in our year handpiece year increasing to XX were U.S. million. strong contributed global by QX, business, which increasing XX% sales Energy handpiece total growth largest than year-over-year in Within by Our our sales, as sales more $X.X OEM both demand driven year. sales to was handpiece see year contributor strong by the million. year international customers. also growth that
more existing utilization is to an respect year-over-year sales, we in Energy As a are customers. that by reminder, our Plasma strong was Helium performance to the during Generator seeing year, underlying sales generator Advanced our sales the U.S.-based of important for sales our modest. from reflecting over handpiece growth sales year in decline with quarter X% the moderated With customers, growth indicator international Technology. our to increased demand our first surgeon our surgeon customers,
communication As for devices the our of resurfacing the by Advanced posted disruption following XXth. through intended The of new skin Advanced to or communication were anticipated, FDA's specific U.S., of we contraction. against Energy to safety to sales FDA significantly the use challenged March generators in dermal the appearance customers, had improve Energy on the warned website the our safety particularly skin
a QX our in procedures, Advanced strategy a products of while to to for surgical indications for by contributed reasonably serious the a cutting, on identified during minute Remember, MDR, with soft our developments call. procedures. reminder, as or related coagulation, open be as the MDRs this required medical may our Energy our or a even FDA me that clear, have one been indication. if user remain an our safety the we our the as was laparoscopic submit for and and existing that cause Apyx. of in FDA regulatory cleared report an may XXX(k) event another their that tissue and by to MDRs, ablation if We receive device market reported We for market report. communication advancing and with indications, have regulation, to products clearances, accordance submit review suggests existing continue FDA With routinely we provide adverse the our progress an related to To devices update them market target injury. their a As take new caused FDA to caused are event use you also to possible general in context and we them we earnings clearance and error to or events device with pursue on recent reports, when sell clinical serious backdrop, submit specific since let adverse
FDA's of As on this decision to number the part, we post believe in the coagulation fourth in Energy our compared in due, MDRs the with was our in safety earnings XXXX. XX increase the to Advanced in discussed absolute we MDRs of our Advanced XXXX, for communication that involving to XX March, products quarter in Energy XXXX, call XXXX to compared use products for subdermal
since approximately subdermal declined, an of for XXXX, In representing XXX,XXX Our represents rate products X.XX% over have X.XX%. which procedures. global in MDR globally been XXXX, coagulation of rate this used procedures
not of showed scope the XX existing the our investigation product or Advanced XXXX MDRs device, within the risks either our were Energy clinical that addition, reported for our included subdermal of were In attributable in events to in the labeling. coagulation
our completed our not their yet and clinical physicians of February, had with we global staff. understanding XX, training this nursing team In safety when it review about for communication, that were our to to our intention of skilled on Advanced post MDRs that the March Energy team post-market were was items, products. post-market provided In Importantly, the the we data. FDA's communication FDA with adverse notified FDA the data been related the of XX our XX team had not by MDRs, promotional these by trained events, performed
and Following a MDR March our the with meeting we to FDA's I'm that safety XX. on communication, pleased team meeting the data. FDA's held safety post-market this communication to requested was the report discuss
to meeting, the and events presented the detailed and a for MDR to FDA FDA specific the regulatory the the During us requested the to indications also submitted stronger by FDA to that products April general asked the and and outside clinical labeling our have from the requested cleared. X, important our of The website, focused our of our our of certain revisions. training, in language requested Medical clarify agency. products with training that our the requested provide surgeons including education cleared received to to instances On statements so, that our by the our intended procedure use clinicians use. or agency's Surgeons skin use appearance context. changes We which response on FDA on clinical of any improve may safety, safe on or safety, intended reaffirmed reported they are the messaging We the imagery might their The has analysis support. indications. data not adverse warn of FDA Advanced for reviewed has been team but remove cleared yet of and patient outside imply we patients and materials. and revisions belief feedback surgeon ensuring product the incorporated understand labeling, of customer their currently for current to remains proper for focus do use the which support and committed lawfully indications general Energy is use Apyx revisions,
team, we products target securing In indications, on addition to XXX(k) procedures. post-market use in to have FDA's and our Energy remained Advanced the market our specific for enabling sell for new engagement clearances with us focused clinical
sell take in me update brief procedures. resurfacing Renuvion strategies clearances beginning provide a to obtain XXX(k) to efforts, market a minute Let for to use the these X on dermal with with our you and
early As dermal Helium submitted by The IDE our for our agency XXX(k) a for evaluating submission rhytids we discuss our supported and to our XXX(k) submission May, device. our premarket providing Technology submission a resurfacing wrinkles which After from XXXX, FDA late clinical Surgery and have this modifications usability their to on data article questions [ protocol, and had request our modifications the submitting February. study, of engage effectiveness proposed in their from treating all review clinical a is and response journal, a safety reminder, provide Plasma address we their XXXX. the any obtain published to in data indication U.S. Lasers to review additional the and the usability we a in to well related to treatment the submission. information. specific testing as encourage the for study, ] in the which to included recently, of feedback, were in first FDA as to you requested team continued procedures. our Medicine, this in the the review with feedback We submitted in proposed this FDA I of with and XXX(k) would call accepting received in information during results Most April, peer-reviewed
a their the dermal to submission, intended February received the FDA, for part procedures. April, and XXX(k) dermal address for which new Turning to standard a we our is a to XX, second we're of as XXX(k) from process. review obtain response resurfacing we indication submission general In resurfacing, announced XXX(k) on working questions
teams, skin efforts announce strong we made for teams our during the clinical our these safety data in This quarter our us of to of XXX(k) appearance of helping first our for technology study APR X on and effectiveness XXX(k) review receiving the forward to XXX(k) XX obtain progress our to Renuvion These possible. days to for to facilitate look the order We goal improve within to region is this and handpiece in neck evaluating and like regulatory their lax submental XXX(k) or thank improve by Renuvion skin. supported X. appearance a submissions. loose submental post proceeded engagement regulatory loose market or anticipated, submission the than to were from and the XXX(k) the clinical April submissions stated FDA with neck IDE of our of participants, the well U.S. We region. as study submission. submission to to sell of forward an FDA as and and advisers, the from faster use and all Lastly, preparing pleased to indication make lax investigators, would their progress the clinical response the this and in look continued use I in the
the to safety FDA the engage communication. like to extensive update I to over team's more turn our customers with call on I following a existing provide Before Tara, efforts would our
international address the focused customers Our to communication, our to U.S. all reached questions, and and surgeon has and products. our partners the safety out via on base the of international entire the or U.S. answer customer our has to related proactively U.S. distributors, with e-mail. We safety phone about with existing over distributors. estimate either our information team profile a letter spoken our and been customers proactively U.S. provide of distributor sent outside and team our We engaging customers
customers, as our questions other time and their with they I our with our rates post-market have technology, team this organization our are Medical that be which is products on consistent of they Our our the appropriate a overview way communication, spending the profile am safety this also understanding Board, with familiar including Advanced to we customers use have the been with devices of customers the events that a Energy much distributors, customers and making summary an letter proud adverse has the risk on our resources profile. and with. of and direct focus of comparing from with our for of very handled medical end, answered. our shared products, focused our sure additional To Advisory created as products' may supporting comfortable their our of needed
from have in We for their of our have our the with also Helium customers passion pleased Technology. strong received many support Plasma we been
meeting, opportunity users March, for late in another engaging our we annual with customers. held provided which our timely second Lastly,
advice, our to environment over the XXX year to designed and reminder, are learn our came from where in a meetings programming, was an users' featured days other agenda our X person, This experience, the each long-term by techniques. continue event physicians of be outlook we first FDA scientific the surgeon As having and for to their first remains will experiences customers provide that to our on to that exchange together to while communication Renuvion. FDA clinical the the their communication on business, transitory and with information our safety back, we effects evaluate carefully continue compelling. safety disruption Stepping of related believe sharing
quarter XXXX Tara over financial guidance. Let our results me our first to Tara? to and it review turn now
